Bone Therapeutics: Next 6 months should be decisive

BUY, Fair Value EUR26 (+31%)
News published on October Friday 9, 2015
Share on

We hosted Bone Therapeutics roadshow with E. Bastianelli (CEO) and W. Goemaere (CFO) yesterday in Paris. Since it raised EUR37m in the context of its Euronext listing in Feb. 2015, we were pleased to see the company delivering in time on its news flow. Looking into the end of the year and H1 2016, news flow should be even more dense. First efficacy data from the osteoporosis phase I/IIa trial expected within the next 6 months could be a game changer which might trigger a partnership.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities